-
公开(公告)号：EP2705853B1
公开(公告)日：2018-07-18
申请号：EP11865292.4
申请日：2011-05-06
CPC分类号： C08B37/006 , A61K39/0283 , A61K2039/58 , A61K2039/6037 , C08B37/0003 , C08L5/00 , C12N2760/16121 , C12P19/26 , Y02A50/476
摘要： For the first time, an O-specific polysaccharide antigen that is a Shigella sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide consisting of 1-100 repeating disaccharide units of O-[4-amino-2-(N-acetyl)amino-2,4-dideoxy-²-D-galactopyranosyl]-(1†’4)-O-[2-(N-acetyl)amino-2-deoxy-±-L-altrpyranuronic acid] linked by (1†’3) bonds to form a polysaccharide chain. The exopolysaccharide has a molecular mass of from 0.4 to 400 kDa, contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity, generating mucosal protection against Shigella sonnei shigellosis by inducing the synthesis of specific antibodies against S. sonnei in mammals, including humans. Without using lipopolysaccharides as the source of production, an exopolysaccharide with a high degree of purity is produced from a liquid phase culture of S. sonnei bacteria by means of a workable industrial method with a high yield. Effective, highly specific and safe vaccines for the prophylaxis and/or treatment of Shigella sonnei shigellosis are developed on the basis of the above-mentioned exopolysaccharide, as well as pharmaceutical compositions with a broad spectrum of action, in particular, in modulating immune response.
-
2.发明公开EXOPOLYSACCHARIDE OF SHIGELLA SONNEI BACTERIA, METHOD FOR PRODUCING SAME, VACCINE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 有权胞外多糖关志贺氏菌，宋内的细菌，方法，以及含疫苗的药物组合物
公开(公告)号：EP2705853A1
公开(公告)日：2014-03-12
申请号：EP11865292.4
申请日：2011-05-06
IPC分类号： A61K39/112 , A61P37/02 , C12N1/00
CPC分类号： C08B37/006 , A61K39/0283 , A61K2039/58 , A61K2039/6037 , C08B37/0003 , C08L5/00 , C12N2760/16121 , C12P19/26 , Y02A50/476
摘要： For the first time, an O-specific polysaccharide antigen that is a Shigella sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide consisting of 1-100 repeating disaccharide units of O-[4-amino-2-(N-acetyl)amino-2,4-dideoxy-β-D-galactopyranosyl]-(1→4)-O-[2-(N-acetyl)amino-2-deoxy-α-L-altrpyranuronic acid] linked by (1→3) bonds to form a polysaccharide chain. The exopolysaccharide has a molecular mass of from 0.4 to 400 kDa, contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity, generating mucosal protection against Shigella sonnei shigellosis by inducing the synthesis of specific antibodies against S. sonnei in mammals, including humans.
Without using lipopolysaccharides as the source of production, an exopolysaccharide with a high degree of purity is produced from a liquid phase culture of S. sonnei bacteria by means of a workable industrial method with a high yield.
Effective, highly specific and safe vaccines for the prophylaxis and/or treatment of Shigella sonnei shigellosis are developed on the basis of the above-mentioned exopolysaccharide, as well as pharmaceutical compositions with a broad spectrum of action, in particular, in modulating immune response.摘要翻译： 首次，O-特异性多糖抗原的是宋内志贺氏菌，相I，胞外多糖已被制备和鉴定那样，说胞外多糖是在细菌荚膜多糖的1-100由重复的二糖单元的形式的真实的天然化合物 O- [4-氨基-2-（N-乙酰基）氨基-2,4-二脱氧²-D-吡喃半乳糖]的 - （1†“4）-O- [2-（N-乙酰基）氨基-2- -deoxy- -L-±altrpyranuronic酸]（1†“3）键，以形成多糖链连接。 的胞外多糖具有从0.4至400 kDa的分子量，含有无毒的脂质组分，即非羟基化的脂肪酸，并且表现出低致热性和高免疫原性，通过诱导特异性抗体的合成产生抗宋内氏痢疾志贺氏菌的粘膜保护 针对哺乳动物，包括人类S.氏菌。 如果不使用脂多糖作为生产源，具有高纯度的胞外多糖是从S.宋内细菌的液相培养由一种可行的工业方法以高收率来制造。 对于宋内氏痢疾志贺氏菌的预防和/或治疗有效的，高度特异性的和安全的疫苗上述胞外多糖的基础上，以及与动作的广谱的药物组合物上发展起来的，特别是在调节免疫应答。
-
3.发明公开METHOD OF ISOLATING BIOLOGICALLY ACTIVE FRACTION CONTAINING CLINICALLY ACCEPTABLE NATIVE SLIPOPOLYSACCHARIDES OBTAINED FROM BACTERIA PRODUCING ENDOTOXIC LIPOPOLYSACCHARIDES 审中-公开式分离方法关内毒素脂多糖的细菌教训，诊疗安全NATIVE SLIPOPOLYSACCHARIDE含有生物活性GROUP
公开(公告)号：EP1539978A1
公开(公告)日：2005-06-15
申请号：EP03761879.0
申请日：2003-06-03
发明人： APARIN, Petr Gennadievich , LVOV, Vyacheslav Leonidovich , ELKINA, Stanislava Ivanovna , GOLOVINA, Marina Eduardovna , SHMIGOL, Vladimir Igorevich
IPC分类号： C12P19/04 , A61K31/739 , A61P37/04
CPC分类号： C08B37/00 , A61K31/739 , A61K35/74 , A61K39/0283 , A61K2039/6068 , Y02A50/476 , Y02A50/484
摘要： A biologically active fraction (BAF) is presented containing mainly S-lipopolysaccharide (LPS) from gram-negative bacteria producing endotoxic LPSs. These fractions are characterized in that in the lipid A of S-LPS the mole ratio of D-glucosamine and beta-hydroxy acids selected from the group comprising beta-hydroxydecanoic, beta-hydroxydodecanoic, beta-hydroxytetradecanoic, beta-hydroxyhexadecanoic, is approximately 2:1-4, and the mole ratio of D-glucosamine and higher fatty acids, connected both by amide and ester links, in the lipid A of S-LPS is approximately 2:3-7. A method of isolating BAF, containing mainly S-LPS from gram-negative bacteria producing endotoxic S-LPSs, is also presented. The obtained BAFs have pyrogenicity at the level of commercial polysaccharide vaccines and low endotoxicity, have high immunogenicity, which makes it possible to use them as vaccines for mammals, including humans. They are an inducer of cytokines and also may be considered to be a prophylactic tolerogenic anti-shock preparation.
-
-
搜索结果
3 条记录 (耗时 0.01 秒)
